ArticleWorld journal of oncology2026
Characterization of Acute Myeloid Leukemia With t(16;21) Translocation: Cytogenetic, Molecular, and Immunophenotypic Findings.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myeloid leukemia (AML) with t(16;21) translocation is an infrequent hematological neoplasia. This study aimed to describe the cytogenetic, molecular and immunophenotypic profiles of this disease. Methods: We conducted a descriptive observational study using secondary data. AML cases with the t(16;21) translocation were identified from the Mitelman database and systematic searches in PubMed, Scopus, SciELO and Genetics and Cytogenetics in Oncology and Hematology databases. Cytogenetic, molecular, immunophenotypic and clinical variables were extracted. We performed descriptive and survival statistical analyses at 2 and 5 years. Results: We identified 103 cases with AML with t(16;21). Most cases were t(16;21)(p11;q22) (n = 90, 87.4%), with recurrent additional abnormalities including +10 (14.4%), -16 (7.8%), add(11) (5.6%), and del(6) (4.4%), while t(16;21)(q24;q22) cases mainly showed +8 (45.5%) and del(9) (18.2%). Conclusions: The cytogenetic, molecular, and immunophenotypic characteristics of AML with t(16;21) vary according to the chromosomal breakpoint. The t(16;21)(p11;q22) translocation was the most frequently reported and was frequently associated with CD56 expression. The findings suggest that patients with t(16;21)(p11;q22) exhibited lower 5-year survival compared with the other group, highlighting the unfavorable outcomes observed in reported cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.